BillionToOne, Inc. (BLLN)
| Market Cap | 4.66B +14.0% |
| Revenue (ttm) | 436.87M +71.9% |
| Net Income | 45.95M |
| EPS | 0.92 |
| Shares Out | 47.77M |
| PE Ratio | 106.29 |
| Forward PE | 116.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 778,824 |
| Open | 99.12 |
| Previous Close | 96.31 |
| Day's Range | 94.11 - 100.01 |
| 52-Week Range | 61.96 - 150.44 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 128.29 (+31.58%) |
| Earnings Date | Nov 4, 2026 |
About BLLN
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for BLLN stock is "Buy." The 12-month stock price target is $128.29, which is an increase of 31.58% from the latest price.
News
Fuzzy Panda reports short position in BillionToOne, issues cautious report
Short seller Fuzzy Panda Research alleges BillionToOne (BLLN), valued at approximately $5.3B and trading at roughly 12x sales, has significant undisclosed operational, regulatory and clinical issues t...
BillionToOne to Participate in the Piper Sandler 38th Annual Healthcare Conference
MENLO PARK, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are a...
BillionToOne Transcript: Stifel 2026 Healthcare Conference 2026
Northstar's oncology differentiation rests on therapy-selection sensitivity and tissue-free response monitoring, with Q3 annualized revenue at $68 million and ~65 sales reps. Prenatal expansion is increasingly focused on health systems, with Epic-enabled volumes expected to begin in Q1-Q2 2027.
BillionToOne Transcript: UBS Global Healthcare Conference
QCT underpins prenatal growth and a push into tissue-free MRD, with Clear scheduled for Dec. 15, 2026. Management expects continued investment alongside profitability, with growth increasingly driven by oncology by late 2027.
BillionToOne price target lowered to $130 from $140 at Piper Sandler
Piper Sandler lowered the firm’s price target on BillionToOne (BLLN) to $130 from $140 and keeps an Overweight rating on the shares. The firm is updating its estimates and price…
BillionToOne price target raised to $135 from $130 at JPMorgan
JPMorgan raised the firm’s price target on BillionToOne (BLLN) to $135 from $130 and keeps an Overweight rating on the shares. The company reported a Q3 revenue beat and volumes…
BillionToOne reports Q3 EPS 32c, consensus 30c
Reports Q3 revenue $122.98M, consensus $115.8M. “Our third quarter was another period of strong execution,” said Dr. Oguzhan Atay, Co-Founder and CEO of BillionToOne (BLLN). “We delivered rapid growth...
BillionToOne raises FY26 revenue view to $460M-$470M from $450M-$465M
Consensus $454.78M. The company said, “BillionToOne (BLLN) now expects full year 2026 total revenue of $460.0 million to $470.0 million, representing growth of 51% to 54% compared to full year…
BillionToOne Earnings Call Transcript: Q3 2026
Q3 revenue rose 47% YoY to $123.0M, with 71% gross margin and an 18% adjusted EBITDA margin. FY 2026 revenue guidance was raised to $460M-$470M, while Northstar Clear is set to launch December 15.
BillionToOne Earnings release: Q3 2026
BillionToOne released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
BillionToOne Slides: Q3 2026
BillionToOne has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
BillionToOne Quarterly report: Q3 2026
BillionToOne has published its Q3 2026 quarterly earnings report on November 4, 2026.
BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are a...
BillionToOne to Participate in Two Upcoming Investor Conferences
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are a...
BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are a...
BillionToOne publishes Northstar Response head-to-head study
BillionToOne (BLLN) announced the publication of the first peer-reviewed head-to-head study comparing Northstar Response, a tissue-free, methylation-based liquid biopsy assay utilizing patented single...
BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response Head-to-head comparison shows 94% ...
BillionToOne price target raised to $128 from $125 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on BillionToOne (BLLN) to $128 from $125 and keeps a Buy rating on the shares. The firm adjusted its models and…
BillionToOne Transcript: Wells Fargo 21st Annual Healthcare Conference
Q2 saw 64% revenue growth and profitability, driven by strong performance in both prenatal and oncology. Expansion into health systems and product innovation are set to accelerate growth, while reimbursement improvements and high-margin strategies support long-term profitability.
BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are acces...
BillionToOne initiated with a Buy at Canaccord
Canaccord analyst Kyle Mikson initiated coverage of BillionToOne (BLLN) with a Buy rating and $120 price target The company’s single-molecule next-generation sequencing and quantitative counting templ...
BillionToOne announces the launch of Northstar Origin
BillionToOne (BLLN) announced the launch of Northstar Origin, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select panel from 84 to 102…
BillionToOne launches Northstar Origin, a new liquid biopsy test
BillionToOne (BLLN) announced the launch of Northstar Origin, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select panel from 84 to 102…
BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin
New add-on test from a single blood draw; BillionToOne also expands Northstar Select® panel to 102 genes MENLO PARK, Calif., Sept. 1, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-gen...
BillionToOne announces publication of study on cfDNA fetal risk assessment
BillionToOne (BLLN) announced publication of A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population in The Green...